mastocytosis
Information
- Disease name
- mastocytosis
- Disease ID
- DOID:350
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00001356 | Completed | Characteristics of Mast Cells in Mastocytosis | May 1993 | May 2002 | |
| NCT00001756 | Completed | Study of Mast Cell Precursors | December 3, 1997 | November 3, 2022 | |
| NCT00001760 | Completed | Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals | January 1998 | December 2001 | |
| NCT00006413 | Completed | Phase 2 | Stem Cell Transplantation to Treat Systemic Mastocytosis | October 13, 2000 | December 14, 2006 |
| NCT00038675 | Completed | N/A | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | June 2001 | November 2013 |
| NCT00050193 | Completed | Cause and Natural Course of Pediatric-Onset Mastocytosis | November 22, 2002 | March 10, 2014 | |
| NCT00255346 | Completed | Phase 2 | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | November 15, 2005 | March 3, 2017 |
| NCT00336076 | Completed | Molecular Mechanisms and Diagnosis of Mastocytosis | July 2004 | July 2009 | |
| NCT00831974 | Completed | Phase 2 | Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis | October 2004 | |
| NCT01266369 | Completed | Phase 2 | Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation | February 2007 | May 2010 |
| NCT01333293 | Completed | Phase 2/Phase 3 | The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients | September 2011 | January 2016 |
| NCT01384513 | Completed | Phase 2 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | August 4, 2011 | November 16, 2022 |
| NCT01481909 | Completed | Phase 2/Phase 3 | Study on Mastocytosis for Rupatadine Treatment | September 2010 | November 2011 |
| NCT02478957 | Completed | Phase 2 | Treatment of Indolent Systemic Mastocytosis With PA101 | June 2015 | June 2016 |
| NCT02503800 | Completed | The Significance of Blood-tryptase and c-Kit Mutation in Insect Venom Immunotherapy | August 2015 | February 15, 2019 | |
| NCT02620254 | Completed | Mast Cell Connect: A Registry for Patients With Mastocytosis | November 2015 | January 2021 | |
| NCT03406325 | Completed | Mast Cell Activation Test in Allergic Disease | February 1, 2018 | December 1, 2019 | |
| NCT00047918 | Completed | Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing | October 2002 | August 2004 | |
| NCT06210698 | Not yet recruiting | Angioedema Biomarker Research Study | January 15, 2024 | February 1, 2026 | |
| NCT06432556 | Not yet recruiting | N/A | Study of Cellular Heterogeneity in Patients With Mastocytosis | June 1, 2024 | June 15, 2026 |
| NCT05186753 | Recruiting | Phase 2 | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | June 27, 2022 | November 2026 |
| NCT00044122 | Recruiting | Study of Factors Regulating Mast Cell Proliferation | September 18, 2002 | ||
| NCT02450396 | Recruiting | Pregnancy and Medically Assisted Conception in Rare Diseases | June 2014 | December 2025 | |
| NCT02760238 | Recruiting | Myeloproliferative Neoplasms (MPNs) Patient Registry | April 2016 | October 2025 | |
| NCT06440148 | Recruiting | Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis | September 1, 2019 | December 31, 2026 | |
| NCT01701843 | Terminated | Phase 2 | Cromoglicate in Mastocytosis | October 2012 | February 2013 |
| NCT00557895 | Terminated | Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders | August 26, 1996 | June 25, 2019 | |
| NCT03340155 | Unknown status | N/A | Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases | October 30, 2017 | October 2022 |
| NCT04615663 | Unknown status | Assessment of Burden Disease in Patients With Mast Cell Disorders | January 28, 2020 | September 15, 2022 | |
| NCT05084872 | Unknown status | Phase 2/Phase 3 | Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients | October 2021 | January 2024 |
- Disase is a (Disease Ontology)
- DOID:9500
- Cross Reference ID (Disease Ontology)
- GARD:6987
- Cross Reference ID (Disease Ontology)
- ICD10CM:D47.09
- Cross Reference ID (Disease Ontology)
- MESH:D008415
- Cross Reference ID (Disease Ontology)
- MIM:154800
- Cross Reference ID (Disease Ontology)
- NCI:C84269
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:78745000
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0024899
- Exact Synonym (Disease Ontology)
- mast cell hyperplasia
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0100495
- ICD10 preferred id (Insert disease from ICD10)
- D0014107
- ICD10 class code (Insert disease from ICD10)
- Q82.2
- MeSH unique ID (MeSH (Medical Subject Headings))
- D008415